Meetings - The ASCO Post

PROSPER RCC: Neoadjuvant Nivolumab Prior to Nephrectomy Followed by Additional Nivolumab in Patients With Renal Cell Carcinoma

The ECOG-ACRIN Cancer Research Group presented data from PROSPER RCC (EA8143), the first randomized phase III trial of neoadjuvant immunotherapy in patients with kidney cancer, at the European Society...

Lung Cancer

Genomics/Genetics

By The ASCO Post Staff / September 2022 / ESMO Congress 2022

Researchers Examine How Air Pollution May Drive Lung Cancer in Never-Smokers

A new mechanism has been identified through which very small pollutant particles in the air may trigger lung cancer in people who have never smoked, paving the way to new prevention approaches and the...

Global Cancer Care

By The ASCO Post Staff / September 2022 / ESMO Congress 2022

ESMO and EONS Announce Launch of PrEvCan

On September 9, the European Society for Medical Oncology (ESMO), together with the European Oncology Nursing Society (EONS), announced the launch of the Europe-wide “Cancer Prevention Across Europe” ...

ESMO Congress 2022

PROSPER RCC: Neoadjuvant Nivolumab Prior to Nephrectomy Followed by Additional Nivolumab in Patients With Renal Cell Carcinoma

Researchers Examine How Air Pollution May Drive Lung Cancer in Never-Smokers

ESMO and EONS Announce Launch of PrEvCan

USPSTF Issues Final Recommendation Statement on Screening for Breast Cancer

Relapsed or Refractory CD7-Positive Leukemia or Lymphoma CAR T-Cell Therapy Plus HSCT Without GVHD Prophylaxis

Premastectomy Radiotherapy, Surgery, and Immediate Breast Reconstruction

Liposomal Irinotecan vs Topotecan in Relapsed Small Cell Lung Cancer

Smoking Cessation Regimens: Does Dose of Therapy Matter?